TY - JOUR T1 - Virological assessment of hospitalized cases of coronavirus disease 2019 JF - medRxiv DO - 10.1101/2020.03.05.20030502 SP - 2020.03.05.20030502 AU - Roman Wölfel AU - Victor M. Corman AU - Wolfgang Guggemos AU - Michael Seilmaier AU - Sabine Zange AU - Marcel A. Müller AU - Daniela Niemeyer AU - Terence C. Jones Kelly AU - Patrick Vollmar AU - Camilla Rothe AU - Michael Hoelscher AU - Tobias Bleicker AU - Sebastian Brünink AU - Julia Schneider AU - Rosina Ehmann AU - Katrin Zwirglmaier AU - Christian Drosten AU - Clemens Wendtner Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/03/08/2020.03.05.20030502.abstract N2 - Coronavirus disease 2019 (COVID-19) is an acute respiratory tract infection that emerged in late 20191,2. Initial outbreaks in China involved 13.8% cases with severe-, and 6.1% with critical courses3. This severe presentation corresponds to the usage of a virus receptor that is expressed predominantly in the lung2,4. By causing an early onset of severe symptoms, this same receptor tropism is thought to have determined pathogenicity but also aided the control of severe acute respiratory syndrome (SARS) in 20035. However, there are reports of COVID-19 cases with mild upper respiratory tract symptoms, suggesting a potential for pre- or oligosymptomatic transmission6-8. There is an urgent need for information on body site - specific virus replication, immunity, and infectivity. Here we provide a detailed virological analysis of nine cases, providing proof of active virus replication in upper respiratory tract tissues. Pharyngeal virus shedding was very high during the first week of symptoms (peak at 7.11 × 108 RNA copies per throat swab, day 4). Infectious virus was readily isolated from throat- and lung-derived samples, but not from stool samples in spite of high virus RNA concentration. Blood and urine never yielded virus. Active replication in the throat was confirmed by viral replicative RNA intermediates in throat samples. Sequence-distinct virus populations were consistently detected in throat- and lung samples of one same patient. Shedding of viral RNA from sputum outlasted the end of symptoms. Seroconversion occurred after 6-12 days, but was not followed by a rapid decline of viral loads. COVID-19 can present as a mild upper respiratory tract illness. Active virus replication in the upper respiratory tract puts prospects of COVID-19 containment in perspective.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by grants from the German Ministry of Research (01KI1723A) and the European Union (602525) to C. D. as well as by the German Bundeswehr Medical ServiceBiodefense Research Program. The funders had no role in study design, data collection and analysis or decision to publish. Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available in the manuscript and the Annex. ER -